


Loading of allogenic bone grafts with
ANTIBIOTICS



The local prophylaxis and therapy of bone infections is carried out with antibiotic-loaded carriers. An aggressive debridement – similar to tumor surgery – of the infected and necrotic bone, soft tissues and foreign materials is mainly carried out in a two stage revision. Reducing the biological burden of pathogens and improving the effectiveness of the patient's immune system and of the antibiotics against surviving pathogens is the goal of treatment. The following describes in detail the loading of allografts with antibiotics and their release.^{1, 2, 3}

Surgical Procedure

Musculoskeletal infections remain one of the most challenging and serious complications in orthopedic and trauma surgery. The mainstay of treatment and the starting point in defect management is the radical surgical debridement of the infected and necrotic tissue as well as the complete removal of extraneous material.

The defect resulting after debridement has to be filled in order to minimise the accumulation of exudate and haematoma and thus not provide an environment for replication of any bacteria that may still be present.

Local PMMA antibiotic beads, which can achieve concentrations up to 1000 times higher than systemic therapy alone, are a method of temporary defect management. After removal of the PMMA antibiotic beads, the defect is finally filled with antibiotic loaded allografts. The local antibiotic treatment of bone infections can only be an adjuvant therapy that does not cause significant systemic burden.^{4, 5}

Long term clinical experience and scientific studies in this context demonstrated that the healing of tissue around the allogenic bone material is not jeopardised by high local antibiotic levels.^{1, 7, 15}

In addition, allografts loaded with antibiotics improve the local milieu in the transplant area, which gives the body's own tissue cells a better chance of winning the so-called „race for the surface“ over the competing pathogenic microorganisms.⁸

Antibiogram

Biopsies from the infected area should be taken for microbiological testing and determination of the susceptibility or resistance of the bacteria to the tested antibiotics (antibiogram).⁶

According to recent findings, good clinical results can only be achieved by means of radical surgical debridement and targeted antibiotics.^{5,6,9}

The selection of the therapy based on the patient related antibiogram is exclusively in the responsibility of the attending physician. The presentation and list of the options for local antibiotics below serve as a non-binding decision aid.³


Rehydration of Allograft C+TBA

Allograft C+TBA is rehydrated before use. Typically, this process is completed after 10 minutes of placing the graft in 0.9% saline solution, Ringer's solution, blood, or antibiotic solution.¹⁰ Bone material and antibiotic solution (ml) are mixed at a ratio of 1:1.

Solubility of Different Antibiotics in Water

The solubility of the antibiotics limits the maximum initial loading because only a certain amount of solution can be absorbed by the allograft. Dosages exceeding this are free in the liquid phase. It is to be expected that these will result in a high initial antibiotic concentration.¹¹

ANTIBIOTIC	SOLUBILITY IN WATER [g/ml]
Vancomycin	0.1
Tobramycin	0.08



Hematogenous bacterial osteomyelitis, 12 year old boy, fistula, x-ray, MRI (a ,b, c); radical debridement, beads implantation, excised fistula, wound closure in layers (d, e, f, g); x-ray after beads implantation – 1st stage revision (h); x-ray after C+TBA allogenic granules implantation (two weeks later) – 2nd stage revision (i); x-ray follow up 18 month (j, k); clinical findings after 1 year (l).

Loading of Allografts with Antibiotics

The allografts are loaded with antibiotics at a ratio of 1:1, which is made from water for injection (WFI) and the respective antibiotic tested in advance in the antibiogram.

The following tables indicate the quantities for preparing 10 ml antibiotic solutions, which can then be used for rehydrating 10 ml Allograft C+TBA.

Mix according to Winkler et al., 2000¹²

ANTIBIOTIC (AB)	AB [g]	WATER [ml]	CONC. [g/l]
Vancomycin	1	10	100
Tobramycin*	0.8	10	80

* Tobramycin and Gentamicin belong to the same antibiotics group of the aminoglycosides.

Mix according to Witsø et al., 2000¹³

ANTIBIOTIC (AB)	AB [g]	WATER [ml]	CONC. [g/l]
Benzylenicillin	1	10	100
Cefalotin	1	10	100
Clindamycin	1.5	10	150
Netilmicin	1	10	100
Vancomycin	0.5	10	50
Ciprofloxacin	0.02	10	2
Rifampicin	0.6	10	60

The treatment of implant-associated infections and osteomyelitis remains a great challenge. Biofilm-associated bacteria show an ongoing reduction of susceptibility to the known antibiotics.

An in-vitro study that was published recently demonstrates that the therapy of *Staphylococcus epidermidis* biofilm with different glycopeptides increases the total biofilm share and that the antibiotics used (Vancomycin, Teicoplanin, Oxacillin, Rifampicin and Gentamicin) have no marked bactericidal effect.¹⁴


However, when Vancomycin or Teicoplanin is combined with Rifampicin, a part of the biofilm of *Staphylococcus epidermidis* is neutralised and positively affects the bactericidal effect.^{5, 6, 9}

Allograft C+TBA as an Antibiotic Carrier: An In Vitro and In Vivo Study

A recent study conducted in cooperation between the Medical University of Innsbruck, the Technical University of Berlin, the University of Niš, and the Justus Liebig University of Giessen aimed to evaluate the efficacy of Allograft C+TBA as a carrier for antibiotics in order to prevent acute infections and promote bone healing.

The study demonstrated that the technique of rehydration of the allograft blocks in antibiotic solutions was both effective and readily implementable. A 10-minute rehydration duration was determined to be sufficient for effective delivery, without compromising the mechanical stability and bony ingrowth of the Allograft C+TBA.

The present study investigated the release of four distinct antibiotics. The results show that the antibiotic release from Allograft C+TBA blocks was sustained above the minimum inhibitory concentration for multiple days, both in vitro and in vivo.¹⁵ Furthermore, the allografts were observed to foster bone remodeling.¹⁵



In vitro release kinetics of allogenic bone blocks loaded with antibiotics up to seven days after incubation in clindamycin (A), vancomycin (B), gentamicin (C), and vancomycin in combination with rifampicin (D). The concentration of vancomycin and vancomycin in combination with rifampicin, gentamicin, and clindamycin in the bone blocks was above the MIC90 for seven, five, and two days respectively. Significant differences (p 0.05) compared to other time points are marked with a star (*) and the associated time point.¹⁵

According to the study, Allograft C+TBA could serve as a viable option for carrying antibiotics during orthopedic and revision surgeries.¹⁵

LITERATURE

- 1 Buttaro MA, et al.
High active local levels of vancomycin without nephro-toxicity released from impacted bone allografts in 20 revision hip arthroplasties. *Acta orthopaedica*. 2005;76(3):336-340.
- 2 Buttaro MA, Pusso R, Piccaluga F.
Vancomycin-supplemented impacted bone allografts in infected hip arthroplasty - two stage revision results. *JBJS, British Volume*. 2005;87(3):314-319.
- 3 McLaren AC.
Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. *Clinical orthopaedics and related research*. 2004;427:101-106.
- 4 Schnettler R, Steinau H-U.
Septic Bone and Joint Surgery. 2010.
- 5 Alt V, Schnettler R, et al.
Rifampicin-fosfomycin coating for cementless endoprostheses: Antimicrobial effects against methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). *Acta biomaterialia*. 2014;10(10):4518-4524.
- 6 Alt V, Franke J, Schnettler R.
Local delivery of antibiotics in the surgical treatment of bone infections. *Techniques in Orthopaedics*. 2015;30(4):230-235.
- 7 Buttaro M, et al.
Incorporation of vancomycin-supplemented bone allografts. *Acta orthopaedica Scandinavica*. 2003;74(5):505-513.
- 8 Subbiahdoss G, et al.
Microbial biofilm growth vs. tissue integration: "The race for the surface" experimentally studied. *Acta biomaterialia*. 2009;5(5):1399-1404.
- 9 Kraus R, Schiefer U, Schnettler R.
In Septic bone and joint surgery, edited by Schnettler R, Steinau H-U. Thieme, 2010.
- 10 C+TBA, Package leaflet and summary of product characteristics.
- 11 Witsø E, et al.
High local concentrations without systemic adverse effects after impaction of netilmicin-impregnated bone. *Acta orthopaedica scandinavica*. 2004;75(3):339-346.
- 12 Winkler H, et al.
In vitro release of vancomycin and tobramycin from impregnated human and bovine bonegrafts. *J. Antimicrob. Chemother*. 2000;46(3):423-428.
- 13 Witsø E, et al.
Cancellous bone as an antibiotic carrier. *Acta Orthopaedica Scandinavica*. 2000;71(1):80-84.
- 14 Claessens J, et al.
Inefficacy of vancomycin and teicoplanin in eradicating and killing staphylococcus epidermidis biofilms in vitro. *Int. J. Antimicrob. Agents*. 2015;45(4):368-375.
- 15 Coraça-Huber DC, Schnettler R, et.al.
Lyophilized human bone allograft as an antibiotic carrier: an in vitro and in vivo study, *Antibiotics*. 2022;11(969):2-16. Verfügbar von <https://doi.org/10.3390/antibiotics11070969>.